Key result
Adverse atrial sarcomere modifications promote atrial cardiomyopathy and AF via downstream inflammatory signaling.
Why the study?
Innovative therapies are needed due to a lack of a comprehensive understanding of the complex mechanisms underlying AF, especially in atrial cardiomyopathy.
Understanding atrial sarcomere-specific mechanisms offers potential for novel therapeutic approaches, including small-molecule sarcomere activators and inhibitors, in treating atrial cardiomyopathy and atrial fibrillation.
Answers are grounded in this paper and cite their sources.
Sarcomere modifications may offer new therapeutic targets in atrial cardiomyopathy; leaves open whether modulators will reduce AF progression in trials.
Innovative therapies are needed in the face of a lack of a comprehensive, in-depth understanding of the complex mechanisms underlying atrial fibrillation (AF). There is recognition of a need for deeper understanding and novel therapeutic approaches, especially in atrial cardiomyopathy (ACM). ACM is considered a separate entity characterized by structural, architectural, contractile, or electrophysiological changes, increasing the potential for clinical atrial pathology. Evidence indicating a role for ACM in atrial disorders is that, in some cases, thromboembolic risk and persistent AF continue despite treatments such as ablation of isolated regions of the pulmonary vein known to set off AF. Here we review a possible role for modifications at the level of atrial sarcomeres as a common mechanism inducing genetic and acquired AF/ACM. Our review indicates the likelihood that these modifications induce adverse signaling resulting in fibrosis, inflammation, neuro-humoral activity, and arrhythmias, in turn promoting atrial pathology. We discuss genetic and acquired ACM through the lens of a new era of understanding of sarcomere control mechanisms. This advanced understanding has not been thoroughly discussed previously in the case of atrial sarcomeres. Significant new evidence has revealed atrial sarcomere specific mechanisms with the potential for novel control of the pressure-volume relation that is vulnerable in ACM. These mechanisms in atrial sarcomeres have taken on new significance with the identification and clinical development of small-molecule sarcomere activators and inhibitors with possible use and further development in ACM therapy.
No takes yet. Share an insight, caveat, or question.
McCauley et al. (2026) conducted a review in Atrial fibrillation and atrial cardiomyopathy. Adverse sarcomere signaling was evaluated. Adverse modifications at the level of atrial sarcomeres likely induce adverse signaling resulting in fibrosis, inflammation, and arrhythmias, promoting atrial cardiomyopathy and atrial fibrillation.
Synapse has enriched 10 related papers. Consider them for comparative context: